Date: 2013-11-11
Type of information:
phase: 1b-2a
Announcement: initiation
Company: GW Pharmaceuticals (UK)
Product: cannabinoids in combination with temozolomide
Action mechanism:
Disease: glioblastoma multiforme (GBM)
Therapeutic area: Cancer - Oncology
Country:
Trial details: This study is a 20-patient, multicentre, two part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, and a double blind, randomised, placebo-controlled phase with patients randomised to active or placebo, and with a primary outcome measure of 6 month progression free survival. The study objective is to assess the tolerability, safety and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ratio, in combination with temozolomide in patients with recurrent GBM. Secondary endpoints include additional pharmacokinetic and biomarker analyses and additional measurable outcomes of tumor response.
Latest
news: